Gilead agrees 127-country remdesivir licence with generic makers
14-05-2020
Gilead backs away from antiviral monopoly after criticism
26-03-2020
China approves three Gilead remdesivir patents for COVID-19 treatment
27-02-2020
Sundry Photography / Shutterstock.com
An association representing Indian cancer patients has asked the country’s government to cancel Gilead Sciences’ patents on remdesivir, the experimental antiviral which is hoped can be used to treat coronavirus.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead, remdesivir, CPAA, COVID-19, coronavirus, cancer, patent, India, orphan drug, antiviral
